Bill > HR7091

This bill, titled the "Expanding Veterans’ Access to Emerging Treatments Act," directs the Secretary of Veterans Affairs to establish a research program within 90 days of enactment to investigate and provide extended access to innovative treatments and emerging therapies for veterans suffering from conditions with unmet medical needs. These "covered conditions" include anxiety, chronic pain, depression, post-traumatic stress disorder (PTSD), substance use disorders, and traumatic brain injury, among others. The program will allow the Department of Veterans Affairs (VA) to conduct clinical trials using treatments such as psilocybin, ketamine, and other investigational therapies, and to develop protocols for compassionate or extended access to these treatments for eligible veterans. The bill also mandates that the Secretary report to Congress within one year on the program's progress, including identified clinics, participant numbers, trial outcomes, and a review of utilized therapies, with the program subject to review and potential extension or termination after two years. Importantly, the bill clarifies that this program must operate in compliance with all applicable federal laws, including those governing investigational medical products and controlled substances.

Health and Social Services, Military Affairs and Security

https://www.congress.gov/bill/119th-congress/house-bill/7091/all-info